IL-18-binding protein protects against lipopolysaccharide- induced lethality and prevents the development of Fas/Fas ligand-mediated models of liver disease in mice.

@article{Faggioni2001IL18bindingPP,
  title={IL-18-binding protein protects against lipopolysaccharide- induced lethality and prevents the development of Fas/Fas ligand-mediated models of liver disease in mice.},
  author={Raffaella Faggioni and Russell C. Cattley and Jian Guo and Sonia Flores and Heidi Brown and Ming Qi and Songmei Yin and David B. Hill and Sheila Scully and Chuangqi Chen and David W. Brankow and Jill B. Lewis and Claudia Baikalov and Hana Yamane and T Meng and Francisco Javier Medrano Martin and Shuxian Hu and Tom Boone and Giorgio Senaldi},
  journal={Journal of immunology},
  year={2001},
  volume={167 10},
  pages={5913-20}
}
IL-18-binding protein (IL-18BP) is a natural IL-18 inhibitor. Human IL-18BP isoform a was produced as fusion construct with human IgG1 Fc and assessed for binding and neutralizing IL-18. IL-18BP-Fc binds human, mouse, and rat IL-18 with high affinity (K(D) 0.3-5 nM) in a BIAcore-based assay. In vitro, IL-18BP-Fc blocks IL-18 (100 ng/ml)-induced IFN-gamma production by KG1 cells (EC(50) = 0.3 microg/ml). In mice challenged with an LD(90) of LPS (15 mg/kg), IL-18BP-Fc (5 mg/kg) administered 10… CONTINUE READING